/
CELZ
$0.81-$0.39 (-32.48%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.4M
4M shares
52-week range
$0.79 – $6.25
0% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
24.40%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-21.29
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $124.4K | $165.5K | $164.5K | $87.8K | $88.6K | $9.0K | $11.0K | $6.0K |
| Cost of revenue | $70.4K | $45.5K | $50.6K | $47.9K | $28.5K | $3.6K | $4.4K | $2.2K |
| Gross profit | $54.0K | $120.0K | $113.9K | $39.8K | $60.1K | $5.4K | $6.6K | $3.8K |
| Gross margin | 43.4% | 72.5% | 69.2% | 45.4% | 67.8% | 60.0% | 60.0% | 63.4% |
| R&D | $96.6K | $0 | $0 | $109.2K | $6.3M | $2.0M | $2.4M | $2.3M |
| Operating income | −$1.1M | −$1.1M | −$1.1M | −$3.1M | −$10.2M | −$5.6M | −$5.7M | −$6.1M |
| EBITDA | −$1.1M | −$6.6M | −$35.0M | $23.6M | −$10.1M | −$5.2M | −$5.4M | −$6.0M |
| Net income | −$13.7M | −$8.5M | −$36.3M | $19.2M | −$10.1M | −$5.3M | −$5.5M | −$6.0M |
| Net margin | -10977.2% | -5126.1% | -22082.2% | 21892.8% | -11449.3% | -58739.7% | -49940.7% | -99916.8% |
| EPS (diluted) | -11351.33 | -5017.67 | -626.88 | 56.10 | -9.28 | -3.76 | -3.71 | -2.52 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $23M | $-1.57 | $-1.57–$-1.57 | 1 |
| 2027 | $34M | $-1.51 | $-1.51–$-1.51 | 1 |
| 2028 | $60M | $-1.46 | $-1.46–$-1.46 | 1 |
| 2029 | $94M | $5.74 | $5.74–$5.74 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.94
Price
$0.81
Implied upside
+263%
Peer comparison
Creative Medical Technology Holdings, Inc. Common Stock
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
www.creativemedicaltechnology.com- Employees
- 4
- IPO / List date
- Apr 30, 2009
- HQ
- PHOENIX, AZ
Held by traders on TradeandTell
No one on the platform currently holds CELZ.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CELZ as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-06-12 | 1-for-10reverse |
| 2021-11-10 | 1-for-500reverse |
| 2020-02-03 | 1-for-150reverse |
Recent trades on TradeandTell
No one on the platform has traded CELZ yet.
